- Conditions
- Non-Small Cell Lung Cancer, Solid Tumor
- Interventions
- Atezolizumab, Standard of Care Chemotherapy, Tiragolumab
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 7
- States / cities
- Fort Myers, Florida • St. Petersburg, Florida • Tallahassee, Florida + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 1,372
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Everolimus, Pemetrexed, Carboplatin, Bevacizumab
- Drug
- Lead sponsor
- Cancer Research and Biostatistics Clinical Trials Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 4
- States / cities
- Tuscon, Arizona • Lexington, Kentucky • Portland, Oregon + 1 more
- Conditions
- Advanced Gastrointestinal Cancer
- Interventions
- BBI608, Fluorouracil, Oxaliplatin, Leucovorin, Irinotecan, Bevacizumab, Capecitabine, Regorafenib
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 495 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Fort Myers, Florida • Atlanta, Georgia + 11 more
- Conditions
- Colorectal Cancer
- Interventions
- bevacizumab, cetuximab, capecitabine, oxaliplatin
- Biological · Drug
- Lead sponsor
- Herbert Hurwitz
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Winston-Salem, North Carolina
- Conditions
- Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
- Interventions
- gemcitabine hydrochloride, cisplatin, bevacizumab, placebo, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific, Cancer
- Interventions
- capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)
- Drug
- Lead sponsor
- Herbert Hurwitz
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 3
- States / cities
- Harvey, Illinois • Durham, North Carolina • Nashville, Tennessee
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Carboplatin, Paclitaxel, Bevacizumab
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 6
- States / cities
- Fort Lauderdale, Florida • Terre Haute, Indiana • Louisville, Kentucky + 3 more
- Conditions
- Lung Cancer
- Interventions
- Pazopanib
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Pittsburgh, Pennsylvania
- Conditions
- Recurrent Glioblastoma, Recurrent Adult Brain Tumor, Gliosarcoma
- Interventions
- HSPPC-96, bevacizumab
- Biological · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 417
- States / cities
- Anchorage, Alaska • Hot Springs, Arkansas • Little Rock, Arkansas + 268 more
- Conditions
- Glioblastoma
- Interventions
- Bevacizumab, Temozolomide, Radiation therapy, Placebo
- Drug · Radiation
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 921 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 6 more
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma
- Interventions
- PF-08046050, bevacizumab, 5-Fluorouracil (5-FU), Oxaliplatin, Leucovorin (LV)
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 914 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 13 more
- Conditions
- Ovarian Cancer, Peritoneal Cancer
- Interventions
- Abraxane, Bevacizumab
- Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Colorectal Cancer, Diarrhea, Neutropenia
- Interventions
- fluorouracil, leucovorin, oxaliplatin
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 5
- States / cities
- Asheville, North Carolina • Greensboro, North Carolina • Greenville, North Carolina + 2 more
- Conditions
- Sarcoma
- Interventions
- Bevacizumab, Doxorubicin, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Prostate Cancer, Adenocarcinoma of the Prostate
- Interventions
- Bevacizumab, Docetaxel
- Drug
- Lead sponsor
- Mary-Ellen Taplin, MD
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Durham, North Carolina
- Conditions
- Non-small Cell Lung Cancer, EGFR-mutant Lung Cancers
- Interventions
- osimertinib, Bevacizumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Childhood Cerebral Anaplastic Astrocytoma, Childhood Oligodendroglioma, Childhood Spinal Cord Neoplasm, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma
- Interventions
- Bevacizumab, Fludeoxyglucose F-18, Irinotecan Hydrochloride
- Biological · Radiation · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 11
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
- Conditions
- Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
- Interventions
- Bevacizumab, Ipilimumab
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 482
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 298 more
- Conditions
- Advanced Ovarian Cancer
- Interventions
- Bevacizumab, Durvalumab, Olaparib, Placebo olaparib, Durvalumab placebo, Carboplatin+Paclitaxel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Female only
- Enrollment
- 1,407 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 26
- States / cities
- Foothill Ranch, California • Los Angeles, California • Orange, California + 22 more
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Computed Tomography Perfusion Imaging
- Radiation
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Glioblastoma Multiforme
- Interventions
- Temozolomide, bevacizumab and bortezomib
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Metastatic Breast Cancer
- Interventions
- Sorafenib, Bevacizumab, Imaging
- Drug · Other
- Lead sponsor
- Hoosier Cancer Research Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 10
- States / cities
- Galesburg, Illinois • Evansville, Indiana • Fort Wayne, Indiana + 5 more
- Conditions
- Glioblastoma Multiforme
- Interventions
- VB-111, Bevacizumab
- Drug
- Lead sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Durham, North Carolina • San Antonio, Texas